III期非小细胞肺癌的治疗：ASCO快速推荐更新

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information.

In 2021, ASCO published a guideline on the management of stage III non–small cell lung cancer (NSCLC), and in 2023, a rapid update of selected recommendations was issued. One randomized controlled trial (RCT), the phase III LAURA trial, presented as an abstract at the ASCO annual meeting and subsequently published in 2024, prompted another update to the recommendations.

Recommendation 5.8

Patients with unresectable stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation may be offered consolidation osimertinib after definitive chemoradiotherapy (platinum-based chemotherapy and thoracic radiation given concurrently or sequentially; Evidence quality: Moderate; Strength of recommendation: Strong).